Supriya Lifescience Joint Managing Director Shivani Wagh Features on Avendus Wealth–Hurun India U35 List 2026
NiveshIQ
NSE: SUPRIYA · Healthcare
Supriya Lifescience Ltd.
₹838.20▼ ₹9.10 (-1.07%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on SUPRIYA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Supriya Lifescience Ltd.
Supriya Lifescience Limited, founded in 1987 and headquartered in Mumbai, specializes in the research, development, manufacture, and sale of bulk drugs and pharmaceutical chemicals across India and internationally. The company’s core revenue drivers include active pharmaceutical ingredients (APIs) for antihistamines, anti-asthmatics, analgesics, antihypertensives, and vitamins, with a reported FY revenue of ₹873 Cr and net income of ₹198 Cr. Recent product launches such as GelHeal wound care solution and Quickblue oral cancer detection kit diversify its portfolio beyond traditional APIs. The firm has faced regulatory scrutiny, filing a petition in the Supreme Court over a High Court order, but has successfully passed all resolutions at its 18th AGM, maintaining operational continuity. Comp
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹570.37 Cr +23.74% | ₹696.49 Cr +22.11% | ₹827.88 Cr +18.86% |
| EBITDA Margin | 30.33% | 37.44% | 35.52% |
| Net Profit | ₹119.11 Cr +32.56% | ₹187.96 Cr +57.80% | ₹209.12 Cr +11.26% |
| EPS | ₹14.80 | ₹23.35 | ₹25.98 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Supriya Lifescience Joint Managing Director Shivani Wagh Features on Avendus Wealth–Hurun India U35 List 2026
Supriya Lifescience (NSEI:SUPRIYA) - Stock Analysis
🔒
+ 3 more stories about Supriya Lifescience Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹190 Cr, PAT ₹24 Cr, EPS ₹2.99, EBITDA margin 25.0%. Growth context: revenue YoY +30.8%, PAT YoY -30.9%, revenue QoQ -31.4%, PAT QoQ -67.6%. Street verdict: strong miss, revenue surprise -36.5%, PAT surprise -67.9%.
Management commentary points to order wins, deal pipeline, and backlog build as the primary near-term growth lever, with...
FY26 (last completed FY): revenue ₹828 Cr, PAT ₹209 Cr, EBITDA margin 35.5%, EPS ₹25.98. Year-on-year: revenue YoY +18.9...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Sanofi India Ltd.Senores Pharmaceuticals Ltd.Shilpa Medicare Ltd.Strides Pharma Science Ltd.Sun Pharma Advanced Research Company Ltd.Sun Pharmaceutical Industries Ltd.Suven Life Sciences Ltd.Syngene International Ltd.Thyrocare Technologies Ltd.Torrent Pharmaceuticals Ltd.Ventive Hospitality Ltd.Vijaya Diagnostic Centre Ltd.
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for SUPRIYA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track SUPRIYA alongside your other holdings
Unlock full SUPRIYA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Supriya Lifescience Ltd.?
NiveshIQ detects active intelligence signals for Supriya Lifescience Ltd. (SUPRIYA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Supriya Lifescience Ltd.?
Supriya Lifescience Ltd. operates in the Healthcare sector with a market capitalisation of ₹567,403.7L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.